Health policy

Concert Announces Clinical Advisory Board, New Medical Policies

Retrieved on: 
星期三, 五月 1, 2024

NASHVILLE, Tenn., May 1, 2024 /PRNewswire/ -- As part of its commitment to provide transparent, evidence-based medical policy and enable accurate reimbursement for a broader set of diagnostic services, Concert today announced the establishment of an advisory board of experts in clinical laboratory medicine and the release of policies for an expanded scope of routine and advanced laboratory testing.

Key Points: 
  • The newly formed board will advise Concert on its clinical laboratory content.
  • "Concert is working to align payers, providers, and labs to enable patient access to evidence-based testing," said Dr. Girish Putcha.
  • Following are brief bios on each member of the new clinical advisory board, in alphabetical order by last name.
  • Recent roles include Director of Laboratory Science at Palmetto's MolDX program, Chief Medical Officer and Clinical Laboratory Director of Freenome, and Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) member.

CUNY SPH'S Sexual and Reproductive Justice Hub receives a major boost in NYS budget

Retrieved on: 
星期三, 五月 1, 2024

The work underway at the SRJ Hub reflects this holistic vision through its research training, and advocacy efforts.

Key Points: 
  • The work underway at the SRJ Hub reflects this holistic vision through its research training, and advocacy efforts.
  • "I was proud to lead the effort to advocate for funding for the Sexual and Reproductive Justice Hub at CUNY SPH," said Assemblymember Jessica González-Rojas.
  • When we invest in sexual and reproductive justice, we are supporting essential health care and socioeconomic stability for every New Yorker.
  • "New York State's funding for CUNY SPH and the Sexual and Reproductive Justice Hub will greatly aid the school's mission-driven commitment to exposing and mitigating these impacts.

Meta-Analysis of Data from Trials of Machine Perfusion Technologies in Liver Transplantation Demonstrates Clinical Advantages of Hypothermic Oxygenated Machine Perfusion (HOPE), according to Bridge to Life Ltd.

Retrieved on: 
星期三, 五月 1, 2024

CHICAGO, May 1, 2024 /PRNewswire/ -- Hypothermic oxygenated machine perfusion (HOPE) of livers awaiting transplantation provides significantly greater outcomes than normothermic machine perfusion (NMP) and ice-box static cold storage (SCS), according to a Cochrane review and meta-analysis of seven clinical trials. The analysis, Machine perfusion in liver transplantation; Cochrane review and meta-analysis, by Samuel James Tingle, MD, et al, Newcastle University, Translational and Clinical Research Institute, Newcastle, United Kingdom; Freeman Hospital, Institute of Transplantation, Newcastle, United Kingdom; Newcastle University, NIHR Blood and Transplant Research Unit, Newcastle, United Kingdom Newcastle University, Translational and Clinical Research Institute, Newcastle, United Kingdom, was shown today in a late-breaker session during The 2024 International Congress of the International Liver Transplantation Society (ILTS) in Houston, Texas.

Key Points: 
  • CHICAGO, May 1, 2024 /PRNewswire/ -- Hypothermic oxygenated machine perfusion (HOPE) of livers awaiting transplantation provides significantly greater outcomes than normothermic machine perfusion (NMP) and ice-box static cold storage (SCS), according to a Cochrane review and meta-analysis of seven clinical trials.
  • The analysis included seven randomized trials (1024 transplant recipients from 1301 randomized/included livers); four compared end-ischemic hypothermic oxygenated perfusion (HOPE) with SCS, and three compared normothermic machine perfusion (NMP) with SCS.
  • Machine perfusion (MP) is a novel method for organ graft preservation before transplantation.
  • In hypothermic oxygenated perfusion (HOPE), donor livers are perfused through the portal vein with a cold (4 °C), acellular, oxygenated fluid at low vascular pressures.

Newborn Screening Emergency: Urgent Call for Action to Identify 10,000+ Undiagnosed Rare Diseases

Retrieved on: 
星期一, 四月 29, 2024

HERDON, Va., April 29, 2024 /PRNewswire-PRWeb/ -- A pressing need for a comprehensive approach to newborn screening (NBS) has prompted advocacy for a collaborative effort between the United States and India. With a recent report (1) finding that delayed diagnosis in rare disease can yield costs ranging from $86,000 to $500,000 per year, coupled with the fact that NBS can be the gateway to early diagnosis and improved outcomes for rare diseases, (2) experts suggest that an alliance between the two nations could pioneer advancements in global health. Dr. Harsha Rajasimha, the Founder of the Indo US Organization for Rare Diseases (IndoUSrare) explains the urgent need for better NBS in both the US and India, "Cross-border collaborations between the US and India is good for all patients with rare diseases globally. The early identification of patients with rare diseases, creation of patient registries, and databases, in India and other countries is an urgent need and pre-requisite to engage the rest of the world in research and global clinical trials."

Key Points: 
  • Most patients with rare diseases remain undiagnosed and unidentified for a long time, especially, in LMICs where newborn screening isn't mandated yet.
  • Newborn screening programs only screen for a small number of metabolic diseases relative to the 10,000+ rare diseases that are known today.
  • Identification of newborn babies with rare diseases can significantly boost the number of new patients identified with rare diseases.
  • The U.S. and India need to lead by example in the fight against rare diseases by advancing expanded NBS.

Pandemic Fatigue and Vaccine Hesitancy Continue to Affect Global Public Health, New 23-country Study in Nature Medicine Reports

Retrieved on: 
星期一, 四月 29, 2024

NEW YORK, April 29, 2024 /PRNewswire/ -- While it found that global uptake of at least one COVID-19 vaccine dose was robust, a new survey published today in Nature Medicine revealed mixed signals about the current acceptance of vaccines generally, especially COVID-19 boosters. The new survey of 23,000 respondents from 23 countries representing more than 60% of the world's population is the fourth in series of studies led annually since 2020 by a team from the City University of New York Graduate School of Public Health and Health Policy (CUNY SPH).

Key Points: 
  • "They represent major obstacles for health practitioners struggling to meet the urgent need to get people caught up on routine immunizations and ready to face the next pandemic."
  • Reported global uptake of at least one COVID-19 vaccine dose rose last year to 87.8%, as compared to 36.9% in 2021 and 70.4% in 2022.
  • In addition, documented spillover effects on routine immunization raise the threat of the reemergence of other childhood and adult vaccine-preventable diseases.
  • The most trusted sources were "my doctor or nurse" and the World Health Organization, averaging 6.9 and 6.5, respectively.

Boise State University Receives the CAHME/Canon Solutions America Award for Sustainability in Healthcare Management Education and Practice

Retrieved on: 
星期四, 四月 25, 2024

CAHME is an accrediting body for academic programs that offer a professional master’s degree in healthcare management education.

Key Points: 
  • CAHME is an accrediting body for academic programs that offer a professional master’s degree in healthcare management education.
  • Every year, the organization partners with Canon Solutions America to recognize educational institutions that strive to instill ideals of sustainability and social responsibility in future healthcare leaders.
  • “Sustainability has become a touchstone of contemporary healthcare management education and practice.
  • “We congratulate Boise State on this prestigious honor.”
    For an in-depth look at Boise State’s MPHSM program, please visit here .

Aspen Ideas: Health Announces Global Health Experts to Speak at Annual Summit

Retrieved on: 
星期二, 四月 23, 2024

Aspen, CO & Washington, DC, April 23, 2024 (GLOBE NEWSWIRE) -- On Friday, the organizers of the Aspen Institute’s annual health summit, Aspen Ideas: Health, announced additional speakers joining its deep pool of health leaders, innovators, and advocates confirmed for this year’s event in Aspen, Colorado from June 20-23, 2024.

Key Points: 
  • Aspen, CO & Washington, DC, April 23, 2024 (GLOBE NEWSWIRE) -- On Friday, the organizers of the Aspen Institute’s annual health summit, Aspen Ideas: Health, announced additional speakers joining its deep pool of health leaders, innovators, and advocates confirmed for this year’s event in Aspen, Colorado from June 20-23, 2024.
  • Atul Gawande, Assistant Administrator for Global Health, U.S. Agency for International Development (USAID)
    Vanessa Kerry, Special Envoy for Climate Change and Health, World Health Organization; Co-Founder and CEO, Seed Global Health
    See a list of previewed speakers here .
  • Aspen Ideas: Health is organized by the Aspen Institute with media partner NBCUniversal News Group.
  • For media: Journalists interested in attending Aspen Ideas: Health are invited to apply for press credentials here .

Toku Inc. Secures FDA Breakthrough Designation for Technology that Identifies Chronic Kidney Disease Risk Through the Eye

Retrieved on: 
星期二, 四月 30, 2024

Toku, Inc., a commercial medical device company specializing in imaging technology and AI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its MyKidneyAI technology.

Key Points: 
  • Toku, Inc., a commercial medical device company specializing in imaging technology and AI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its MyKidneyAI technology.
  • MyKidneyAI uses AI to analyze retinal images collected at routine eye exams to detect elevated chronic kidney disease (CKD) risk in people with diabetes.
  • Toku developed MyKidneyAI to help identify individuals with diabetes who have elevated CKD risk via a simple eye exam available in eye care or primary care settings.
  • FDA's Breakthrough designation expedites the review process, shortening the time until technology reaches patients if cleared by the FDA.

University of Phoenix College of Nursing Faculty Leadership Selected for Prestigious Fellows of the American Association of Nurse Practitioners® Program

Retrieved on: 
星期五, 四月 19, 2024

The American Association of Nurse Practitioners® (AANP) recognizes the outstanding achievements and exemplary service of 33 AANP members who have been accepted into the prestigious FAANP program.

Key Points: 
  • The American Association of Nurse Practitioners® (AANP) recognizes the outstanding achievements and exemplary service of 33 AANP members who have been accepted into the prestigious FAANP program.
  • “It is an honor to be inducted into the Fellows of the American Association of Nurse Practitioners,” states Jones.
  • “The College of Nursing congratulates Dr. Sun Jones on her induction into the Fellows of the American Association of Nurse Practitioners,” shares Raelene Brooks, Ph.D., RN, dean of College of Nursing at University of Phoenix.
  • In 2024, Jones was selected to co-present, alongside other leaders from the University of Phoenix College of Nursing, during a prestigious podium presentation at the American Association of Colleges of Nursing Diversity Symposium.

AdaptHealth Appoints Suzanne Foster as Chief Executive Officer

Retrieved on: 
星期三, 四月 17, 2024

AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that its Board of Directors has named Suzanne Foster as its Chief Executive Officer.

Key Points: 
  • AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that its Board of Directors has named Suzanne Foster as its Chief Executive Officer.
  • Ms. Foster will assume leadership of the Company from interim CEO and Chairman of the Board, Richard Barasch, on May 20, 2024.
  • Ms. Foster holds an MPH in Law and Health Policy from Harvard University and a JD from Suffolk University Law School.
  • We are grateful for his dedication to AdaptHealth and know he is delivering a healthy business to Suzanne.